Pancreatic Cancer Research

ResearcherUniversity of BernActive in the last 2 years

Matteo Rossi Sebastiano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9925-1904; OpenAlex author ID A5083290928, A5136374342. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 4

  1. Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. Co-author DOI 10.1016/j.celrep.2026.117188↗
  2. Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. Co-author DOI 10.1016/j.celrep.2026.117453↗
  3. Restriction of extracellular lipids renders pancreatic cancer dependent on autophagy. First author DOI 10.1186/s13046-021-02231-y↗
  4. ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression. Co-author DOI 10.1126/sciadv.abb9200↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Georgia Konstantinidou · 4 shared papers, 2020–2026 · strength 0.78
  2. Maciej Garczyk · 2 shared papers, 2026 · strength 0.47
  3. Martin Wartenberg · 2 shared papers, 2026 · strength 0.47
  4. Beat Gloor · 2 shared papers, 2026 · strength 0.47
  5. Maria Saliakoura · 2 shared papers, 2020–2022 · strength 0.31
  6. Eva Karamitopoulou · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.